FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer
Oliveira, M., Saura, C., Nuciforo, P., Calvo, I., Andersen, J., Passos-Coelho, J.L., Gil Gil, M., Bermejo, B., Patt, D.A., Ciruelos, E., de la Peña, L., Xu, N., Wongchenko, M., Shi, Z., Singel, S.M., Isakoff, S.J.
Published in Annals of oncology (01.08.2019)
Published in Annals of oncology (01.08.2019)
Get full text
Journal Article
A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis
Brufsky, A., Kim, S.B., Zvirbule, Ž., Eniu, A., Mebis, J., Sohn, J.H., Wongchenko, M., Chohan, S., Amin, R., Yan, Y., McNally, V., Miles, D., Loi, S.
Published in Annals of oncology (01.05.2021)
Published in Annals of oncology (01.05.2021)
Get full text
Journal Article
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
Hellmann, M.D., Kim, T.-W., Lee, C.B., Goh, B.-C., Miller, W.H., Oh, D.-Y., Jamal, R., Chee, C.-E., Chow, L.Q.M., Gainor, J.F., Desai, J., Solomon, B.J., Das Thakur, M., Pitcher, B., Foster, P., Hernandez, G., Wongchenko, M.J., Cha, E., Bang, Y.-J., Siu, L.L., Bendell, J.
Published in Annals of oncology (01.07.2019)
Published in Annals of oncology (01.07.2019)
Get full text
Journal Article
A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Wagle, M, Eiring, A M, Wongchenko, M, Lu, S, Guan, Y, Wang, Y, Lackner, M, Amler, L, Hampton, G, Deininger, M W, O'Hare, T, Yan, Y
Published in Leukemia (01.07.2016)
Published in Leukemia (01.07.2016)
Get full text
Journal Article
Exploratory biomarker analysis of first-line cobimetinib (C) + paclitaxel (P) in patients (pts) with advanced triple-negative breast cancer (TNBC) from the phase 2 COLET study
Wongchenko, M, Miles, D, Kim, S.B, Xu, N, Amler, L, Yan, Y, Simmons, B, McNally, V, Brufsky, A
Published in European journal of cancer (1990) (01.12.2016)
Published in European journal of cancer (1990) (01.12.2016)
Get full text
Journal Article
25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study
McArthur, G, Larkin, J, Dréno, B, Ascierto, P, Liszkay, G, Maio, M, Mandal´, M, Demidov, L, Stroyakovskiy, D, Thomas, L, De la Cruz-Merino, L, Atkinson, V, Dutriaux, C, Garbe, C, Wongchenko, M, Hsu, J, Koralek, D, Rooney, I, Yan, Y, Ribas, A
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
SO-32 Biomarker analysis of the phase III IMblaze370 trial of atezolizumab plus cobimetinib or atezolizumab monotherapy vs regorafenib in third-line CRC
Argiles, G., Bendell, J., Kim, T., Wongchenko, M., DuPree, K., Mahrus, S., Qu, X., Shi, Y., Uyei, A., Roberts, L., Yan, Y., Ciardiello, F.
Published in Annals of oncology (01.07.2020)
Published in Annals of oncology (01.07.2020)
Get full text
Journal Article
Abstract OT2-01-02: COLET: A multistage, phase 2 study evaluating the safety and efficacy of a doublet regimen of cobimetinib (C) in combination with paclitaxel (P) or triplet regimens of C in combination with atezolizumab (atezo) plus either P or nab-paclitaxel (nab-P) in metastatic triple-negative breast cancer (TNBC)
Miles, D, Kim, S-B, McNally, V, Simmons, B, Wongchenko, M, Xu, N, Brufsky, A
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Get full text
Journal Article
283MO Ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC): Primary results from Cohort B of the IPATunity130 randomised phase III trial
Turner, N., Dent, R., O'Shaughnessy, J., Kim, S-B., Isakoff, S., Barrios, C.H., Saji, S., Bondarenko, I., Nowecki, Z., Lian, Q., Reilly, S-J., Hinton, H., Wongchenko, M., Mani, A., Oliveira, M.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC)
de Bono, J.S., De Giorgi, U., Massard, C., Bracarda, S., Nava Rodrigues, D., Kocak, I., Font, A., Arija, J. Arranz, Shih, K., Radavoi, G.D., Yu, W., Chan, W., Gendreau, S., Zhang, L., Riisnaes, R., Wongchenko, M.J., Maslyar, D., Jinga, V.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
139O Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC)
Dent, R., Oliveira, M., Isakoff, S.J., Im, S-A., Espié, M., Blau, S., Tan, A.R., Saura, C., Wongchenko, M., Xu, N., Bradley, D., Reilly, S-J., Mani, A., Kim, S-B.
Published in Annals of oncology (01.05.2020)
Published in Annals of oncology (01.05.2020)
Get full text
Journal Article
454 - Exploratory biomarker analysis of first-line cobimetinib (C) + paclitaxel (P) in patients (pts) with advanced triple-negative breast cancer (TNBC) from the phase 2 COLET study
Wongchenko, M., Miles, D., Kim, S.B., Xu, N., Amler, L., Yan, Y., Simmons, B., McNally, V., Brufsky, A.
Published in European journal of cancer (1990) (01.12.2016)
Published in European journal of cancer (1990) (01.12.2016)
Get full text
Journal Article
A09 Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Therapeutic Vulnerabilities in Lung Cancer
Daemen, A., Cooper, J.E., Myrta, S., Wongchenko, M., Lin, E., Long, J.E., Foreman, O., Modrusan, Z., Tremayne, J., de la Cruz, C., Merchant, M., Martin, S.E., Yan, Y., Junttila, M.R.
Published in Journal of thoracic oncology (01.02.2020)
Published in Journal of thoracic oncology (01.02.2020)
Get full text
Journal Article
Cell-free (cf)DNA analysis identifies PIK3CA/AKT1 mutations associated with greater PFS improvement from the addition of ipatasertib (IPAT) to paclitaxel (P) in triple-negative breast cancer (TNBC)
Wongchenko, M., Dent, R., Kim, S-B., Saura, C., Oliveira, M., Baselga, J., Kapp, A.V., Chan, W.Y., Singel, S.M., Maslyar, D.J., Gendreau, S.
Published in Annals of oncology (01.09.2017)
Published in Annals of oncology (01.09.2017)
Get full text
Journal Article
Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I
Brufsky, A, Miles, D, Zvirbule, Z, Eniu, A, Lopez-Miranda, E, Seo, JH, Orditura, M, Le Du, F, Wongchenko, M, Poulin-Costello, M, Simmons, B, McNally, V, Loi, S, Kim, S-B
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Get full text
Journal Article
Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation–positive melanoma receiving adjuvant vemurafenib
Ascierto, P.A., Lewis, K.D., Di Giacomo, A.M., Demidov, L., Mandalà, M., Bondarenko, I., Herbert, C., Mackiewicz, A., Rutkowski, P., Guminski, A., Simmons, B., Ye, C., Hooper, G., Wongchenko, M.J., Goodman, G.R., Yan, Y., Schadendorf, D.
Published in Annals of oncology (01.01.2020)
Published in Annals of oncology (01.01.2020)
Get full text
Journal Article
Prognostic impact of early complete metabolic response on FDG-PET, in BRAF V600 mutant metastatic melanoma patients treated with combination vemurafenib & cobimetinib
Xu, W., Frederickson, J., Callahan, J., Ribas, A., Gonzalez, R., Pavlick, A.C., Hamid, O., Gajewski, T., Puzanov, I., Daud, A., Colburn, D., Choong, N., Wongchenko, M., Hicks, R., McArthur, G.A.
Published in Annals of oncology (01.09.2017)
Published in Annals of oncology (01.09.2017)
Get full text
Journal Article
Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone
Yan, Y., Robert, C., Larkin, J., Ascierto, P.A., Dreno, B., Maio, M., Garbe, C., Chapman, P.B., Sosman, J.A., Wongchenko, M.J., Hsu, J.J., Chang, I., Caro, I., Rooney, I., McArthur, G., Ribas, A.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
Abstract P4-22-22: Cobimetinib (C) combined with paclitaxel (P) as a first-line treatment in patients (pts) with advanced triple-negative breast cancer (COLET study): Updated clinical and biomarker results
Brufsky, A, Kim, S-B, Velu, T, García-Saenz, JA, Tan-Chiu, E, Sohn, JH, Dirix, L, Borms, MV, Liu, M-C, Moezi, MM, Kozloff, MF, Sparano, JA, Xu, N, Wongchenko, M, Simmons, B, McNally, V, Miles, D
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Get full text
Journal Article
1093PDVEMURAFENIB AND COBIMETINIB POTENTLY INHIBIT PS6 SIGNALING IN BRAFV600 MUTATION–POSITIVE LOCALLY ADVANCED OR METASTATIC MELANOMA FROM BRIM7 STUDY
Yan, Y., McArthur, G., Gajewski, T., Puzanov, I., Hamid, O., Gonzalez, R., Wang, Y., Lu, S., Wongchenko, M., Choong, N.W., Ribas, A.
Published in Annals of oncology (01.09.2014)
Published in Annals of oncology (01.09.2014)
Get full text
Journal Article